Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Uk Mhra Gmp
  6. /
  7. GLAXOSMITHKLINE
Uk Mhra Gmp
•GLAXOSMITHKLINE•November 10, 2020

GLAXOSMITHKLINE – UK MHRA GMP Certificate UK API 4 Insp GMP 4/117769-0021 [H]

Record Details

This Uk Mhra Gmp record concerns GLAXOSMITHKLINE, with an inspection on November 10, 2020, issued by the MHRA, covering drugs.

Company
GLAXOSMITHKLINE
Compliance status
GMPC
Certificate type
GMP
Inspection date
November 10, 2020
Issued
November 27, 2020
MIA number
UK API 4
Site address
COBDEN STREET, MONTROSE, DD10 8EA, UNITED KINGDOM
Country
UNITED KINGDOM
Products
Human Medicinal Products
Manufacturing operations
[1000000992] ZANAMIVIR [1000007791] DUTASTERIDE [2000008220] FLUTICASONE PROPIONATE [4000013535] VILANTEROL TRIFENATATE [1000008398] ALUMINIUM PHOSPHATE [2000008014] CLOBETASOL PROPIONATE [2000008358] BETAMETHASONE VALERATE [2000014516] FLUTICASONE FUROATE [2000008013] CLOBETASONE BUTYRATE [1000007375] LACIDIPINE [2000007742] SALBUTAMOL SULPHATE [4000003016] ABACAVIR SULFATE Active Substances 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES ZANAMIVIR 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Rehumidification, Blending, Sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing (excluding sterility testing) DUTASTERIDE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing FLUTICASONE PROPIONATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Sieving. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing VILANTEROL TRIFENATATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing ALUMINIUM PHOSPHATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.4  Other Inorganic sterile salt suspension 3.4 Manufacture of sterile active substance 3.4.2  Terminally sterilised 3.5 General Finishing Steps 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.3  Microbiological testing (including sterility testing) CLOBETASOL PROPIONATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Sieving. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing BETAMETHASONE VALERATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, micronisation. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing FLUTICASONE FUROATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing CLOBETASONE BUTYRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, micronisation. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing LACIDIPINE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Sieving. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing SALBUTAMOL SULPHATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Sulphate salt formation and crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Sieving. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing ABACAVIR SULFATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation and salt formation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Seiving. 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing
View Company Profile

ID · dcea37c1-0f3c-4ed9-bdfe-8af144a873ed

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GLAXOSMITHKLINE
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.